MINISTRY-OF-HAJJ-UMRAH
27.12.2022 13:16:42 CET | Business Wire | Press release
Under the patronage of H.R.H Prince Khaled Al-Faisal, Advisor to the Custodian of the Two Holy Mosques and Governor of Makkah Region, the Ministry of Hajj and Umrah will be organizing the ‘Hajj Expo 2023’ conference and exhibition, on 9-12 January 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221227005098/en/
His Royal Highness Prince Khaled Al-Faisal, Advisor to the Custodian of the Two Holy Mosques, Governor of Makkah Region (Photo: AETOSWire)
The four-day event is part of the Ministry's ongoing efforts to build an innovative ecosystem of services and solutions to better serve pilgrims at the Two Holy Mosques, while enhancing their religious and cultural experiences. It aims to create an integrated and sustainable ecosystem that improves pilgrims’ experiences, anticipate their future trends, and establish opportunities for further collaborations, agreements, and local and international initiatives.
H.E. Minister of Hajj and Umrah, Dr. Tawfiq bin Fawzan Al-Rabiah, said: “The conference will allow entrepreneurs, innovators, and researchers from more than 200 global organizations to share successful experiences, and brainstorm sustainable quality solutions designed to cater to pilgrims’ aspirations and needs. This reflects the unrelenting support dedicated by the Custodian of the Two Holy Mosques, and HH the Crown Prince to the Hajj and Umrah sector, in line with the Saudi Vision 2030.”
With delegations from over 56 countries, ‘Expo Hajj’ is expected to witness the signing of 400 agreements and partnerships. It will feature 10 keynote sessions, 13 panel discussions and ‘Hajj Talks’, as well as 36 workshops and related events and activities, notably the Islamic exposition and the ‘Hajj Hackathon’.
‘Hajj Expo 2023’ will be sponsored by several entities and companies, including Kidana Development Company, Elm, Al Wukalla Company, Catering Contractors Association, Muslim World League, Rua AlMadinah Holding, Motawifs Pilgrims for Southeast Asian Countries Co., Alrajhi Umrah, Dallah Albaraka Holding, Sadu Business Solutions, The Company for Cooperative Insurance (Tawuniya), and Saudi Arabia Railways (SAR), Saudi Public Transport Company (SAPTCO), Mohamed Yousuf Naghi Motors Co., Flynas, Saudi Al-Qaid Transportation Co., Alif Alif FM, High Point Technology Company, and Casablanca Company for Hotel & Touristic Services Co. LTD.
The 2021 edition of the conference saw record numbers with +45,000 attendees and 115 commercial agreements. The second edition will feature a wide range of scientific sessions, workshops, and training programs, with several ministers of Islamic affairs, endowments and Hajj ambassadors and consuls, and Hajj and Umrah operators from around the world.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221227005098/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom